Major depression (MD) and bipolar disorder (BD) are severe and potentially life-threating mood disorders whose etiology is to date not completely understood. MicroRNAs (miRNAs) are small non-coding RNAs that regulate protein synthesis post-transcriptionally by base-pairing to target gene mRNAs. Growing evidence indicated that miRNAs might play a key role in the pathogenesis of neuropsychiatric disorders and in the action of psychotropic drugs. On these bases, in this study 1 These authors contributed equally to this work 2 we evaluated the expression levels of the entire miRNome 1733 mature miRNAs annotated in miRBase v.17, through a microarray technique, in the blood of 20 MD and 20 BD patients and 20 healthy controls, in order to identify putative miRNA signatures associated with mood disorders.
Introduction
Major Depression (MD) and Bipolar Disorder (BD) are mood disorders recognized by the World Health Organization as major causes of disability worldwide, as they frequently prevent affected individuals from leading independent lives and hold features of chronicity and potential life threat.
Several hypotheses, focused on alterations in monoamine neurotransmitters and their related signalling or, more recently, on the involvement of other biological pathways, particularly those regulating neurogenesis and neuroplasticity mechanisms (Pittenger and Duman, 2008) , neuroimmune function (Müller and Schwarz, 2007) and glutamatergic neurotrasmission (Popoli et al., 2011) have been proposed to explain the pathogenesis of these disorders. However, the etiology and pathophysiology of MD and BD are still not completely understood, thus limiting the hypothesis-driven discovery of novel therapeutic targets.
One of the major issues that still need to be addressed in mood disorders concerns the possibility to dissect MD from BD, since these pathologies show overlapping symptoms and can be misdiagnosed (Hirschfeld, 2013) . Moreover, a correct differential diagnosis of MD or BD is crucial for an appropriate treatment from the onset and, in turn, for successful treatment outcomes. As a consequence, the identification of biomarkers, that can reflect MD-and BD-specific pathophysiologic processes, may be helpful and also provide novel biological targets for the development of personalized treatments (Culpepper, 2014) .
MicroRNAs (miRNAs) are evolutionary conserved, small non-coding RNAs (20) (21) (22) Besides their presence in cells, miRNAs were also observed in a highly stable cell-free form in body fluids (Cortez et al., 2011) and were detected in several peripheral biological matrices, including whole blood, plasma, serum, cerebrospinal fluid (CSF) and saliva, among the others miRNAs expression levels in periphery and some pathological tissues suggests that the evaluation of their concentrations could provide useful biomarkers for several diseases (Laterza et al., 2009; Skog et al., 2008) . A handful of studies has shown miRNA level modifications in peripheral tissues (in particular, blood and its derivatives) from MD patients, both compared to healthy controls and following pharmacotherapy, whereas only one study is available for BD. These findings are summarized in Table 1 .
The first study on peripheral miRNAs expression in drug-free MD patients was conducted by our research group. We evaluated miRNA level changes in the whole blood of depressed patients after 12 weeks of antidepressant treatment with escitalopram, reporting a significant modulation for 30 miRNAs, potentially implicated in several biological pathways associated with brain functions (Bocchio-Chiavetto et al., 2013). Other studies conducted on peripheral blood mononuclear cells from MD patients, compared to healthy controls, reported a differential expression of 14 (Belzeaux et al., 2012 ) and 5 miRNAs (Fan et al., 2014) . Moreover, after an effective 8-weeks treatment with different classes of antidepressant drugs, a modulation was detected for 8 miRNAs (Belzeaux et al., 2012) . Furthermore, an increase in the levels of 2 miRNAs, targeting the neurotrophin brain-derived neurotrophic factor (BDNF), was observed in the serum of MD patients (Li et al., 2013) . More recently, an intriguing study evidenced a decrease in both post-mortem brains and plasma from MD patients in the levels of miR-1202, a miRNA regulating glutamate receptor (GRM4) expression.
Moreover, miR-1202 plasma levels were modulated by antidepressant treatment and correlated with clinical response (Lopez et al., 2014) . Finally, a decrease in miR-135, a miRNA regulating serotonergic neuron activity, was found in both post-mortem brains and blood of MD patients (Issler et al., 2014) . Concerning BD, only one study was conducted to date in peripheral tissues, reporting a decrease in plasma miR-134 levels in BD drug-free patients during manic phase compared to healthy controls; consistently, the miRNA content increased after a 4-weeks treatment with different combinations of antipsychotics and/or mood stabilizers (Rong et al., 2011) . However, no studies have been conducted to date comparing miRNA peripheral levels in MD and BD patients in order to identify potential markers useful for the differential diagnosis. Based on these lines of evidence, the aim of the present study was to investigate, by using a hypothesis-free approach, putative alterations in blood miRNA profiles related to the pathogenesis of MD and BD, in order to identify possible shared or specific signatures associated with these mood disorders.
Materials and methods

Study participants
Twenty patients with MD and 20 with BD (10 type I and 10 type II) were recruited. They had to 
Blood collection and storage
Peripheral venous blood samples were collected from all the patients and controls in PAXGene tubes in the morning, after an overnight fast. The tubes were kept at room temperature for 2 hours, then frozen at -20 °C for 24 hours and finally moved to a -80 °C freezer, according to the manufacturer's instructions. The tubes were finally sent for analysis in dry ice.
MicroRNA isolation and expression analysis by microarray
Total RNA was extracted from 2.5 mL of blood with the PAXGene Blood miRNA Kit (Qiagen, CA, USA), designed for the simultaneous isolation of small and large RNAs; RNA concentration and quality were assessed through a NanoDrop spectrophotometer (Thermo Scientific, MA, USA).
A volume corresponding to 500 ng of total RNA from each blood sample was processed with the Raw data were imported and analyzed with the software Partek Genomic Suite 6.6 (Partek, St.
Louis, MO, USA). Principal-component analysis (PCA) was carried out to identify outliers and the statistical analysis for the evaluation of differences in miRNA levels was performed by Analysis of variance (ANOVA) test, with 3 comparisons: BD patients vs controls, MD patients vs controls and BD patients vs MD patients. As cut-offs for the identification of the differentially expressed miRNAs, fold changes (FCs) < -1.2 or > 1.2 and FDR < 0.05 were considered.
Real-time PCR validation
Among the miRNAs found as significantly modulated from the microarrays data, we selected for validation in Real Time PCR (RT-PCR) those that were in common between MD and BD patients and those that had already been implicated in psychiatric disorders or in antidepressant treatment by other studies or had been involved in brain functions relevant for mood disorders. In this selection we did not consider the more recently annotated miRNAs, as still scarcely studied.
For the selected miRNAs, RT-PCR was conducted using the TaqMan MicroRNA Assays (Applied Biosystems, CA, USA), following the manufacturer's instructions; the reactions were run on the
StepOnePlus instrument (Applied Biosystems). The Ct values were normalized according to the deltaCt (dCt) method on the endogenous controls RNU44 and RNU48. The normalization stability score of these small nucleolar RNAs was confirmed by the analysis with the geNorm software.
The differential expression analysis was performed according to the deltadelta (ddCt) method by applying a t-test, whereas putative correlations of miRNA expression levels with subject's gender and age were assessed with the Pearson's test.
Statistical analysis
Data were expressed as mean ± standard deviation. 
Target gene prediction and pathway analysis
A gene set enrichment analysis was conducted on the putatively regulated target genes of the differentially expressed miRNAs. The goal was to identify the biological processes that might be affected by the miRNAs differentially expressed in MD and BD patients as compared to controls.
To this purpose, the first step was the identification of the miRNA targets. Since the experimentally validated miRNAs-mRNAs interactions represent a relatively small subset with respect to potential interactions, a number of computational prediction tools have been developed to generate sets of candidate target genes for a given miRNA. However, the different tools often lead to a significant variability in target genes lists due to the differences in the used prediction algorithms. This is mainly because the different tools are based on the evaluation of distinct properties (e.g., thermodynamics and evolutionary conservations) and thus they provide complementary information. In order to have a more reliable prediction, we exploited ComiR, a combinatorial miRNA target prediction tool integrating the information retrieved from some of the most wellknown target prediction algorithms, including Miranda, PITA, TargetScan and mirSVR.
Specifically, this prediction tool computes each algorithmic score and generates as output the combined probability of a gene to be regulated by an individual miRNA or sets of miRNAs using a support vector machine method (Coronnello and Benos, 2013) . Using ComiR, we computed the probabilities of interaction between the miRNAs differently regulated and all the annotated 3'UTR sequences retrieved from ENSEMBL database.
We performed the analysis considering the different sets of differentially expressed miRNAs, namely: miRNAs associated with MD, miRNAs associated with BD and miRNAs commonly regulated between MD and BD. In order to classify whether or not a given gene had to be considered as a "good" miRNA target, we arbitrarily chose a medium-stringent threshold in the interaction probability computed by ComiR (i.e., 0.9), to include in the analysis only interactions that are more likely to occur. We performed the enrichment analysis using the tool David (Huang et al., 2009) , with respect to the KEGG pathways potentially affected by miRNA expression variations.
Results
Socio-demographic and clinical characteristics of study participants
There was a prevalence of female gender in the MD subgroup (17/20, 85%) compared to the BD subgroup (12/20, 60.0%), although without a significant difference (p > 0.05). BD patients showed an earlier age at onset of the disorder than MD patients (24 vs 40.7 years; p < 0.001) and a longer duration of illness (19.55 vs 8.70; p < 0.01). The severity of the depressive symptomatology at the study inclusion was similar in the two subgroups, as revealed by the scores of the assessment scales, and no other significant difference in demographic and clinical variables between MD and BD subgroups was present ( Table 2 ). All the patients were drug-naïve or drug-free from antidepressant and mood stabilizer drugs. 
MicroRNA expression analysis
The miRNome analysis identified sets of miRNAs altered in MD and BD patients as compared to controls and a subset of miRNAs up-regulated in both patient groups. In particular, as shown in the Venn Diagram (Figure 1 ), 7 miRNAs were differentially expressed in MD patients with respect to controls: hsa-let-7a-5p, hsa-let-7d-5p, has-let-7f-5p, hsa-miR-1915-3p (down-regulated) and hsamiR-199a-5p, hsa-miR-24-3p, hsa-miR-425-3p (up-regulated). Thirteen miRNAs were altered in BD patients as compared to controls: hsa-miR-720, hsa-miR-140-3p, hsa-miR-1973, hsa-miR-30d-5p, hsa-miR-3158-3p, hsa-miR-330-5p, hsa-miR-378a-5p, hsa-miR-4521, hsa-miR-21-3p (upregulated) and hsa-miR-1915-5p, hsa-miR-1972, hsa-miR-4793-3p, hsa-miR-4440 (downregulated). Finally, 3 miRNAs were similarly up-regulated in MD and BD patients (hsa-miR-29c-5p, hsa-miR-330-3p, hsa-miR-345-5p).
<Figure 1 here>
No significant difference was observed comparing miRNA blood levels in MD vs BD patients.
Significant data are reported in Table 3 , whereas the results about all the 1733 mature miRNAs analyzed are shown in Supplementary Table 1. Considering microarray expression analysis and literature information (see Materials and Methods),
we selected for RT-PCR validation a total number of 13 miRNAs: 5 from the comparison between MD patients and controls (hsa-let-7a-5p, hsa-let-7d-5p, hsa-let-7f-5p, hsa-miR-24-3p, hsa-miR-425-3p), 5 from the comparison between BD patients and controls (hsa-miR-140-3p, hsa-miR-30d-5p, hsa-miR-330-5p, hsa-miR-378a-5p; hsa-miR-21-3p), and the 3 commonly up-regulated in MD and BD patients vs controls (hsa-miR-29c-5p, hsa-miR-330-3p, hsa-miR-345-5p). RT-PCR results confirmed all the significant differences (Table 4 and Figure 2 ) except for hsa-miR-29c-5p, which didn't reach the statistical significance although the FC was in the same direction of the microarray analysis. Moreover, significant differences were also observed between MD and BD patients for all the analyzed miRNAs. Overall, a highly significant correlation (r = 0.93, p < 0.001) between the miRNA FCs obtained from microarray and RT-PCR analysis was found. 
Target gene prediction and pathway analysis
With the aim to identify biological processes affected by the differentially expressed miRNAs, we first predicted the potentially regulated mRNAs and then we performed an enrichment analysis to infer putative biological pathways involved in miRNA regulation. The target gene prediction analysis was carried out considering the interaction score between 21684 ENSG gene IDs and all the miRNAs confirmed by RT-PCR as differentially expressed in MD and BD patients. We detected 229 mRNAs regulated by MD-specific miRNAs, 486 mRNAs regulated by BD-specific miRNAs, and 227 mRNAs which represent targets of the miRNAs commonly regulated in MD and BD (Supplementary Table 2 ). Notably, some sets of miRNAs, and in particular the 3 belonging to the let-7 family, acted mostly on the same gene targets. Indeed, the hierarchical cluster analysis clearly identified a coordinated regulated action exerted by hsa-let-7a-5p, hsa-let-7d-5p and hsa-let-7f-5p.
The resulted dendrogram obtained using Ward's clustering method in R environment is reported in Figure 3 .
<Figure 3 here>
The subsequent enrichment analysis of the identified target genes with respect to the KEGG pathway database showed a significant over-representation of several pathways putatively altered in MD and BD disorders (Table 3 ). In particular we found that, although some miRNAs were specifically modulated in MD or BD as compared to controls, some of their target genes belong to pathways that are significantly modulated in both the diseases, including Wnt signaling pathway, 
Discussion
In this study, by assessing the whole miRNome expression in the blood of MD and BD patients (all drug-naïve or drug-free from antidepressants and mood stabilizers), we observed a dysregulation in a number of miRNA transcripts, some specific for MD or BD, whereas others common to both the diseases. Moreover, the RT-PCR results also evidenced significant differences, in terms of miRNA levels, between MD and BD patients.
Regarding MD, RT-PCR validation assays confirmed a significant increase of miR-24-3p and miR-425-3p levels and a decrease for let-7a-5p, let-7d-5p and let-7f-5p expression. These miRNAs were previously implicated in psychiatric diseases, as well as in neuronal molecular mechanisms and behavioural functions. In particular, miR-24-3p was suggested to be a main hypothalamic regulator of oxytocin (Choi et al., 2013) , the neuropeptide that regulates several social behaviours such as Let-7 miRNAs belong to the most highly expressed miRNAs in the human brain (Anacker and Beery, 2013) and are supposed to exert a powerful influence on gene expression in the CNS. In particular, let-7 miRNAs exert a pivotal action on neuronal differentiation and maturation during neurodevelopment (Shao et al., 2010) and also on neurogenesis and neuronal plasticity functions in the adult brain.
Our data are consistent, since they showed a down-regulation in MD patients of 3 miRNAs belonging to the let-7 family that are able to regulate almost the same target genes (Figure 3 ).
Moreover, these 3 miRNAs are coded in the same genetic cluster on chromosome 9 (hsa-let-7a-5p, chr9 94175957-94176036; hsa-let-7d-5p, chr9 94176347-94176433; hsa-let-7f-5p, chr9 94178834-94178920), suggesting a possible impaired transcriptional co-regulation.
Concerning the BD-specific miRNAs, we found an increased blood content of miR-30d-5p, miR-140-3p, miR-330-5p, miR-21-3p and miR-378a-5p. The blood expression of miR-30d-5p and miR-140-3p was increased also in MD patients after AD treatment in our previous study ( to clarify the observed modifications. We are also aware that the sample size of this study is small and further confirmation in larger samples is needed. Finally, most of the enrolled patients were drug-free, but not drug-naïve from psychotropic drugs, so we can't exclude an influence of previous therapies on the observed results.
In conclusion, here we report a peripheral blood dysregulation in the expression levels of a panel of miRNAs specific for MD or BD patients, together with common alterations, which could potentially influence several pathways relevant for brain functions. The identification of the genes and biological pathways controlled by these miRNAs could provide new information for clarifying the pathogenesis of these diseases. Moreover, although further studies in larger samples are needed, the described miRNA alterations may provide potential biomarkers, which could be integrated with clinical and other biological information to enhance the diagnosis and treatment of mood disorders.
49. Tardito, D., Seguini, M., Mallei, A., Merelli, I., Corrada, D., Bocchio-Chiavetto, L, Racagni, G.,  5 miRNAs are specifically altered in the blood of BD patients in a depressive phase.
 2 miRNAs are commonly altered in both the mood disorders.
 The dysregulated miRNAs potentially affect the expression of brain-relevant genes. Only the genes which are targeted by at least one miRNA are included.
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